Cargando…
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study
INTRODUCTION: Topical immunotherapy is frequently used in the treatment of alopecia areata (AA) although few studies report long-term follow-up. Our goals were to determine the efficacy and the prognostic factors of topical immunotherapy in a large cohort of patients with AA treated in the departmen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825331/ https://www.ncbi.nlm.nih.gov/pubmed/29442292 http://dx.doi.org/10.1007/s13555-018-0226-5 |
_version_ | 1783302173782704128 |
---|---|
author | Zerbinati, Nicola Esposito, Cristina D’Este, Edoardo Calligaro, Alberto Valsecchi, Rossano |
author_facet | Zerbinati, Nicola Esposito, Cristina D’Este, Edoardo Calligaro, Alberto Valsecchi, Rossano |
author_sort | Zerbinati, Nicola |
collection | PubMed |
description | INTRODUCTION: Topical immunotherapy is frequently used in the treatment of alopecia areata (AA) although few studies report long-term follow-up. Our goals were to determine the efficacy and the prognostic factors of topical immunotherapy in a large cohort of patients with AA treated in the departments of Dermatology and Venereology of Bergamo, Como and Pavia, from 1978 to January 2016. METHODS: A total of 252 patients with AA were evaluated retrospectively. RESULTS: All our patients developed an allergic reaction to a 2% solution of dinitrochlorobenzene (DNCB) or squaric acid dibutylester (SADBE) or diphenylcyclopropenone (DPCP). No patients discontinued therapy because of side effects. In total 112 patients (44.05%, p < 0.001) had a good response. Statistical analysis revealed that the main prognostic factors influencing the clinical results were the severity of hair loss at the beginning of therapy, the duration of AA, a history of atopy (particularly eczema), and the early development of sensitization to the three sensitizers. CONCLUSION: Topical immunotherapy in patients with AA is quite effective, mostly well tolerated, and provides prolonged therapeutic benefits. |
format | Online Article Text |
id | pubmed-5825331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-58253312018-02-28 Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study Zerbinati, Nicola Esposito, Cristina D’Este, Edoardo Calligaro, Alberto Valsecchi, Rossano Dermatol Ther (Heidelb) Original Research INTRODUCTION: Topical immunotherapy is frequently used in the treatment of alopecia areata (AA) although few studies report long-term follow-up. Our goals were to determine the efficacy and the prognostic factors of topical immunotherapy in a large cohort of patients with AA treated in the departments of Dermatology and Venereology of Bergamo, Como and Pavia, from 1978 to January 2016. METHODS: A total of 252 patients with AA were evaluated retrospectively. RESULTS: All our patients developed an allergic reaction to a 2% solution of dinitrochlorobenzene (DNCB) or squaric acid dibutylester (SADBE) or diphenylcyclopropenone (DPCP). No patients discontinued therapy because of side effects. In total 112 patients (44.05%, p < 0.001) had a good response. Statistical analysis revealed that the main prognostic factors influencing the clinical results were the severity of hair loss at the beginning of therapy, the duration of AA, a history of atopy (particularly eczema), and the early development of sensitization to the three sensitizers. CONCLUSION: Topical immunotherapy in patients with AA is quite effective, mostly well tolerated, and provides prolonged therapeutic benefits. Springer Healthcare 2018-02-13 /pmc/articles/PMC5825331/ /pubmed/29442292 http://dx.doi.org/10.1007/s13555-018-0226-5 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Zerbinati, Nicola Esposito, Cristina D’Este, Edoardo Calligaro, Alberto Valsecchi, Rossano Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title | Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title_full | Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title_fullStr | Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title_full_unstemmed | Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title_short | Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study |
title_sort | topical immunotherapy of alopecia areata: a large retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825331/ https://www.ncbi.nlm.nih.gov/pubmed/29442292 http://dx.doi.org/10.1007/s13555-018-0226-5 |
work_keys_str_mv | AT zerbinatinicola topicalimmunotherapyofalopeciaareataalargeretrospectivestudy AT espositocristina topicalimmunotherapyofalopeciaareataalargeretrospectivestudy AT desteedoardo topicalimmunotherapyofalopeciaareataalargeretrospectivestudy AT calligaroalberto topicalimmunotherapyofalopeciaareataalargeretrospectivestudy AT valsecchirossano topicalimmunotherapyofalopeciaareataalargeretrospectivestudy |